JAGX
Jaguar Health, Inc.
$2.80
-8.20%
$1.8M
No data for this timeframe.
Vol
Market Cap$1.8M
Cap SizeNano Cap
Inst. Holders1 funds
Inst. Value$28.00
Inst. Activity1 buys / 0 sells
Reddit Sentiment50° Neutral
SEC Reports10
Recent Activity
Jun 2, 2026
SEC
Jaguar Health entered into two exchange agreements with Streeterville Capital, converting 7.92 shares of Series Q Prefer
8-K — Impact 6/10
May 29, 2026
SEC
Jaguar Health filed a DEFA14A supplement to its definitive proxy statement, clarifying terms of Proposal 3 (equity line
DEFA14A — Impact 4/10
May 27, 2026
SEC
Jaguar Health received formal notice from Nasdaq on May 26, 2026 that it has regained compliance with the $1.00 bid pric
8-K — Impact 4/10
Dec 11, 2025
Insider
MICEK JOHN sold 7,377 shares
Director @ $0.00 ($0.00)
Dec 11, 2025
Insider
MICEK JOHN sold 7,377 shares
Director @ $0.00 ($0.00)
Inst.
BANK OF AMERICA CORP — DOUBLED
30 shares ($28.00)
Inst.
BANK OF AMERICA CORP — DOUBLED
14 shares ($33.00)
Dec 21, 2026
fda_pdufa
PDUFA: JAGX — Canalevia in diarrhea in dogs — 2026-12-21
FDA target action date 2026-12-21 for JAGX (Jaguar Health, Inc.). Drug: Canalevia. Indication: diarr
Price Targets
Historical data — last covering-analyst action May 2025. No current recommendation available.
$262.50 (May 2025)
Current $2.80
Low $262.50
Median $262.50
High $262.50
1 analysts
$262.50
$262.50
Analyst Ratings
3Strong Buy
3Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 19, 2025 | First Berlin | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current FY | $-4.20 ▲ +96.2% | $-4.20 — $-4.20 | 99% YoY | 1 |
| Next FY | $-9.45 ▲ +32.5% | $-9.45 — $-9.45 | -125% YoY | 1 |
Latest Reports
BEARISH
8-K
6/10
Jaguar Health entered into two exchange agreements with Streeterville Capital, converting 7.92 shares of Series Q Prefer
Jun 2, 2026
NEUTRAL
DEFA14A
4/10
Jaguar Health filed a DEFA14A supplement to its definitive proxy statement, clarifying terms of Proposal 3 (equity line
May 29, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BANK OF AMERICA CORP | $28.00 | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Dec 11, 2025 | MICEK JOHN | A | $0.00 |
| Dec 11, 2025 | MICEK JOHN | A | $0.00 |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
1 institutional holders with $28.00 total value (30 shares) as of 2025-Q4. Top holders: BANK. Net buying activity: 1 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BANK OF AMERICA CORP /DE/ | 30 | $28.00 | 100.0% | DOUBLED +114.3% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | DOUBLED | 14 | 30 | +114.3% | $28.00 | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 4 | 14 | +250.0% | $33.00 | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 11,173 | 1 | -100.0% | $2.00 | 2025-Q3 |
| UBS Group AG | DOUBLED | 4,315 | 11,173 | +158.9% | $28.2K | 2025-Q2 |
| UBS Group AG | NEW | — | 4,315 | — | $20.5K | 2025-Q1 |
| VANGUARD GROUP INC | EXIT | 59,503 | 0 | -100.0% | $0.00 | 2025-Q1 |
| UBS Group AG | EXIT | 50,657 | 0 | -100.0% | $0.00 | 2025-Q1 |
| UBS Group AG | ADD | 33,762 | 50,657 | +50.0% | $51.2K | 2024-Q4 |
1 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Dec 11, 2025 | MICEK JOHN | Director | A | 7,377 | $0.00 | $0.00 |
| Dec 11, 2025 | MICEK JOHN | Director | A | 7,377 | $0.00 | $0.00 |
10 SEC filing reports analyzed. Sentiment: 0 bullish, 5 bearish, 1 mixed, 4 neutral. Avg impact: 5.5/10.
BEARISH
8-K
6/10
Jaguar Health entered into two exchange agreements with Streeterville Capital, converting 7.92 share
Jun 2, 2026
NEUTRAL
DEFA14A
4/10
Jaguar Health filed a DEFA14A supplement to its definitive proxy statement, clarifying terms of Prop
May 29, 2026
NEUTRAL
8-K
4/10
Jaguar Health received formal notice from Nasdaq on May 26, 2026 that it has regained compliance wit
May 27, 2026
BEARISH
8-K
6/10
Jaguar Health issued 54,222 common shares to Streeterville Capital in exchange for the cancellation
May 22, 2026
MIXED
8-K
6/10
Jaguar Health entered into exchange agreements with Uptown Capital and Streeterville Capital, issuin
May 19, 2026
NEUTRAL
DEFA14A
1/10
Jaguar Health filed a DEFA14A supplement to correct a typographical error in its April 30, 2026 prox
May 6, 2026
BEARISH
8-K
8/10
Jaguar Health received a Nasdaq delisting notice on May 1, 2026, due to insufficient publicly held s
May 4, 2026
BEARISH
8-K
8/10
Jaguar Health received a conditional extension from Nasdaq to maintain its listing by demonstrating
Apr 27, 2026
NEUTRAL
8-K
5/10
Jaguar Health's stockholders approved a series of capital structure proposals including increasing a
Apr 21, 2026
BEARISH
8-K
7/10
Jaguar Health reported 2025 financial results showing a 5% sequential increase in Q4 2025 revenue to
Apr 7, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action May 2025): 86% buy across 7 analysts — 3 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action May 2025. No current recommendation available.
$262.50 mean target (May 2025)
$262.50 Low
$262.50 High
| Metric | Value |
|---|---|
| Current Price | $2.80 |
| Target Low | $262.50 |
| Target Mean | $262.50 |
| Target Median | $262.50 |
| Target High | $262.50 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2026-12-31 |
$-4.20 | $-4.20 | $-4.20 | 99.5% | +96.2% | 1↑ 0↓ | $0.0B | 77.8% | 1 |
| Next FY 2027-12-31 |
$-9.45 | $-9.45 | $-9.45 | -125.0% | +32.5% | 1↑ 0↓ | $0.0B | -31.0% | 1 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 19, 2025 | First Berlin | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
1 mentions
0 bullish
0 bearish
1 time period
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Feb 5, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
tell me i’m stupid
▲ 11
💬 10
⚡ 0.1
Dec 21, 2026
fda_pdufa
PDUFA: JAGX — Canalevia in diarrhea in dogs — 2026-12-21
FDA target action date 2026-12-21 for JAGX (Jaguar Health, Inc.). Drug: Canalevia. Indication: diarrhea in dogs. Current conditional Regulatory Approv
May 20, 2026
earnings_calendar
JAGX Q1 2026 Earnings Scheduled — 2026-05-20
May 13, 2026
earnings_calendar
JAGX Q1 2026 Earnings Scheduled — 2026-05-13
Apr 8, 2026
short_volume
Short Volume: JAGX — 58.7% short (0.5M / 0.8M)
Short: 455,050 | Exempt: 120 | TRF Vol: 775,859 | Short Ratio: 58.7% | Off-exchange volume (dark pool + OTC)
Mar 30, 2026
earnings_calendar
JAGX Q4 2025 Earnings After Market Close — 2026-03-30